Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07606066 · ClinicalTrials.gov registry record
A Study to Identify and Characterize Patients With Type 2 Diabetes Mellitus for Possible Participation in Ongoing or Future Type 2 Diabetes Mellitus Clinical Studies
A clinical trial, sponsored by AstraZeneca.
- Recruiting
- Registry status
- 2,150
- Enrollment target
NCT07606066: Recruiting study, sponsored by AstraZeneca.
NCT07606066 is a clinical trial that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 2,150 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07606066 is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- 2,150 participants
- Enrollment target
Study Summary
The purpose of this study is to identify and characterize patients with known Type 2 Diabetes Mellitus (T2DM) for possible participation in ongoing or future T2DM clinical studies, and to characterize trends in key concomitant medication use in this patient population across different geographical regions.
Primary Outcome
Summary statistics
Interventions
- OTHER Procedure: assessment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,150 participants |
| Start Date | 2026-05-06 |
| Est. Completion | 2027-03-31 |
What NCT07606066 shows while recruiting
NCT07606066 is an observational study that tracks outcomes without assigning an intervention. Its 2,150 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Procedure: assessment is the first listed.
NCT07606066 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07606066 about?
NCT07606066 is a clinical study titled "A Study to Identify and Characterize Patients With Type 2 Diabetes Mellitus for Possible Participation in Ongoing or Future Type 2 Diabetes Mellitus Clinical Studies". The purpose of this study is to identify and characterize patients with known Type 2 Diabetes Mellitus (T2DM) for possible participation in ongoing or future T2DM clinical studies, and to characterize trends in key concomitant medication use in this patient population across different geographical r...
What is the current status of trial NCT07606066?
This trial is currently recruiting. The enrollment target is 2,150 participants. The study started on 2026-05-06. Estimated completion is 2027-03-31.
What interventions are being tested in trial NCT07606066?
The interventions under investigation include: Procedure: assessment (OTHER).
Who is sponsoring clinical trial NCT07606066?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06783335 · 2,150 participants
Real World Effectiveness of the Cordella Pulmonary Artery Sensor System in Patients With Chronic Heart Heart Failure
- NCT05805709 · 2,145 participants · NA
A Patient-centered Trial of a Process-of-care Intervention in Hospitalized AKI Patients: the COPE-AKI Trial
- NCT06598475 · 2,142 participants · NA
Investigating Facilitator-driven, Multi-level Implementation Strategies in Federally Qualified Health Centers to Improve Provider Recommendation and HPV Vaccination Rates Among Latino/a Adolescents
- NCT05742178 · 2,160 participants · NA
NYC Cancer Outreach Network in Neighborhoods for Equity and Community Translation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI